Filing Details

Accession Number:
0001209191-20-006959
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-02-05 16:52:45
Reporting Period:
2020-02-03
Accepted Time:
2020-02-05 16:52:45
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
875320 Vertex Pharmaceuticals Inc / Ma VRTX Pharmaceutical Preparations (2834) 043039129
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1446372 M Paul Silva C/O Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Boston MA 02210
Svp & Controller No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-02-03 1,290 $91.05 19,049 No 4 M Direct
Common Stock Acquisiton 2020-02-03 809 $86.52 19,858 No 4 M Direct
Common Stock Disposition 2020-02-03 210 $228.91 19,648 No 4 S Direct
Common Stock Disposition 2020-02-03 240 $230.28 19,408 No 4 S Direct
Common Stock Disposition 2020-02-03 809 $231.03 18,599 No 4 S Direct
Common Stock Disposition 2020-02-03 630 $231.46 17,969 No 4 S Direct
Common Stock Disposition 2020-02-03 210 $232.75 17,759 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2020-02-03 1,290 $0.00 1,290 $91.05
Common Stock Stock Option (Right to Buy) Disposition 2020-02-03 809 $0.00 809 $86.52
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2026-02-01 No 4 M Direct
3,236 2027-02-02 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 169 Indirect 401(k)
Footnotes
  1. Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1.
  2. Open market sales reported on this line occurred at a weighted average price of $228.91 (range $228.37 to $229.24).
  3. Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
  4. Open market sales reported on this line occurred at a weighted average price of $230.28 (range $229.92 to $230.53).
  5. Open market sales reported on this line occurred at a weighted average price of $231.46 (range $231.21 to $231.63).
  6. Open market sales reported on this line occurred at a weighted average price of $232.75 (range $232.26 to $233.21).
  7. Fully vested.
  8. The option vests in 16 quarterly installments from 02/03/2017.